Axsome Reports Accelerated AUVELITY Prescriptions as Alzheimer’s Launch Progresses
Axsome Therapeutics reported a significant increase in new-to-brand prescriptions for its drug AUVELITY, reaching a record high of 3,800 weekly. The growth is attributed to the recent launch of the medication for treating agitation associated with Alzheimer's disease and an expanded sales force. Patients aged 65 and older now account for about 31% of new-to-brand prescriptions, up from around 19% before the indication’s approval. Axsome reiterated its long-term peak-sales outlook of $8 billion for AUVELITY, evenly split between major depressive disorder and Alzheimer's disease agitation. The company also noted strong market access with 89% coverage across total lives insured and first-line or first-switch status in most plans. Management expects operating expenses to remain stable while revenue grows faster, supporting a path toward profitability. The firm is advancing its pipeline programs including solriamfetol studies, AXS-12 development, and a Phase 3 trial of AUVELITY for smoking cessation.
Tickers: $AXSM
Topics: Alzheimer's disease agitation AUVELITY Axsome Therapeutics prescription trends